Skyline Investment

Skyline Investment was founded by Jerzy Rey, who led the firm's spinout from CA IB in 1997. As a publicly listed entity on the Warsaw Stock Exchange, investment decisions are governed by its management board and supervised by a supervisory board. Day-to-day allocation authority rests with the management team under Polish corporate law, though specific named decision-makers beyond the founding group are not routinely disclosed in English-language reporting.

Skyline is structured as a publicly traded holding company that makes direct private-equity investments. It does not raise traditional closed-end blind-pool funds with fixed lifespans. The permanent-capital structure means it is not forced to sell portfolio companies on a predetermined schedule and can hold assets indefinitely, operating more like a listed investment company than a conventional general partner.

Skyline's anchor portfolio is concentrated in Poland, where it maintains a legacy real-estate book in Warsaw and a series of technology and healthcare holdings. The firm's stated mandate extends to Central and Eastern Europe, though the bulk of its confirmed, named portfolio companies remain Polish-domiciled. Public filings do not indicate a large-scale expansion into other CEE jurisdictions in recent periods.

Skyline draws on a network built over nearly three decades in the Polish market, originally rooted in the corporate-finance relationships of the CA IB team that founded the firm. As a publicly listed entity, it can also use its own scrip as acquisition currency in merger transactions — a sourcing and structuring mechanism not available to conventional private GPs. Specific deal-sourcing practices are not elaborated in English-language public disclosures.

Skyline's mandate spans buyout, growth equity, and venture capital, depending on the asset and the cycle. Historically it was most active in mid-market buyouts and restructurings. In recent years the firm has shifted toward earlier-stage technology and life-science ventures, evidenced by its positions in companies like MedApp and Nestmedic, while continuing to manage legacy real-estate holdings.